NCT07089290Not yet recruiting
A Study Protocol to Assess the Effectiveness of Nurse-Led Telehealth Intervention for Hypertension Control in Nepal
Effectiveness of Nurse-Led Telehealth Intervention for Hypertension Control in Nepal
Source: ClinicalTrials.gov · Last updated 28 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Despite being the leading cause of cardiovascular diseases and premature death worldwide, hypertension control remains a largely unmet challenge for public health systems even in developed countries. Hypertension control in Nepal is challenging due to decreased awareness, limited access to the health facilities caused by geographical constraints and health care personnel shortage. Telehealth can help address these gaps and nurse-led telehealth can be a better option as nurses can provide timely follow up, track patients' progress and offer guidance on medication adherence and lifestyle changes which are crucial for hypertension control. This study aims to evaluate the effectiveness of nurse-led telehealth for hypertension control among hypertensive adults in Nepal. We will use the Intervention Mapping (IM) approach to develop a theory-based and evidenced nurse-led telehealth intervention for hypertension control. Following IM, a parallel-group 1:1 randomized control trial 353 participants in each group will be used to evaluate the effectiveness of intervention. The intervention consists of regular BP monitoring, video conferencing and virtual drug adjustment. The follow up will be done in 3 and 6 months. Explanatory Sequential mixed Method will be used to assess the acceptability, appropriateness, and feasibility of adapting nurse-led telehealth for hypertension control. Data collection will utilize a self-constructed semi-structured questionnaire, along with validated questionnaires. The collected data will be analyzed using STATA 14, contributing valuable insights into the potential impact of nurse-led telehealth interventions on increasing hypertension control.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 706 (estimated)
- First submitted
- 14 Jul 2025
- Start date
- 1 Nov 2025
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Kathmandu University School of Medical Sciences
- Diseases
- High blood pressure
- NCT number
- NCT07089290
What you commit to
- Study type: Interventional
- Planned participants: 706
- From 1 Nov 2025 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Had a stroke in the past 30 days or are on dialysis
- Individuals with self-reported serious advanced illness such as terminal cancer
Other
- Pregnant women
- Patients in hypertensive crisis (BP ≥180/120 mm Hg)
- Patients enrolled in other BP research during the same period
Who the study is looking for
- Aged 30 years and above
- Blood pressure at baseline of more than 140 or 90 mm Hg on at least two separate visits or under antihypertensive medications
- Willing to monitor their blood pressure and self-titrate medication
- Possess a smartphone with internet access and WhatsApp/Viber at least biweekly
- No cognitive deficit and able to communicate effectively to carry out study tasks
- Not planning to change residence during the 6-month follow-up
Age in the registry: 30 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kathmandu University School of Medical Sciences Coordinator of this site? Confirm its status | Dhulikhel | Nepal | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.